ILC Therapeutics

ILC Therapeutics Ltd is an early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Cancer, Atopic Dermatitis and Psoriasis. Our hybrid, patented, interferon alpha has been shown to have a powerful stimulatory effect on NK cells and this is critical to maintaining NK cell activity inside tumours where the cancer is trying to switch them off and escape destruction. Our Hybrid 1 has shown modulatory effects on tissue based ILC-2 networks (Atopic Dermatitis) and ILC-3 networks associated with Psoriasis. All these applications have massive market potential driven by unmet clinical need or under performance of existing therapies. We expect that alone or in combination with current standard of care we have can have a significant clinical impact in the future.

Contact details

www.ILCtherapeutics.com
ILC Therapeutics